Caribou Biosciences Inc (CRBU) 옵션

CRBU, new 52 week low

what a piece of shit stock this you need to be very selective People got duped when

Pfizer bought some shares here at

On June 30, 2023, Pfizer invested $25 million in Caribou Biosciences, purchasing 4.69 million shares at $5.33 per share, boosting the gene-editing company's funding for its cell therapy programs.

https://www.cariboubio.com/pipeline/

Founder of CRSP on board here a lot of companies that fail in this space!

Jennifer Doudna, PhD

Jennifer is a co-founder of Caribou Biosciences. She is a professor of molecular and cell biology and chemistry at the University of California, Berkeley where she is the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences; the president of the Innovative Genomics Institute; and investigator at the Howard Hughes Medical Institute; a senior investigator at the Gladstone Institutes; a faculty scientist in the physical biosciences division of Lawrence Berkeley National Laboratory; and a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Her research seeks to understand how non-coding RNA molecules control the expression of genetic information and she has published extensively in the field of CRISPR-Cas biology. Jennifer’s work and that of her collaborator Dr. Emmanuelle Charpentier was recognized by the award of the Nobel Prize in Chemistry 2020 as well as a 2015 Breakthrough Prize. Her work on CRISPR-Cas systems has also been recognized with the Paul Janssen Award for Biomedical Research, a Lurie Prize in Biomedical Sciences, and the Princess of Asturias award. Jennifer was also named to the 2015 TIME Magazine’s TIME 100 list of the 100 most influential people in the world. After serving as a member of the Yale University faculty for eight years, during which time she was promoted to Henry Ford II Professor of Molecular Biophysics and Biochemistry, she joined the University of California, Berkeley faculty in 2002. Jennifer earned a PhD in biochemistry from Harvard University and was a postdoctoral scholar at the University of Colorado Boulder.


$CRBU

What do you think of their shift to partial HLA matching?

CRBU. Under $2

CRBU under $2

CRBU READY TO BEAST

CRBU...NEW SCAN JUST GAVE ME THIS BIO

CRBU under $3

CRBU under $2

CRBU under $3

CRBU under $3

Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.

CRBU under $3

CRBU new 52 week low

CRBU new 52 week low

Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase

Any good news in here comming?

Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.

The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.

CRBU new 52 week low

Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…

It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.

CRBU new 52 week low

CRBU new 52 week low

CRBU under $5

It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???

CRBU new 52 week low

Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.

.

$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo

Didn't they buy TRIL? Just gambling with billions from US government.

PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html

Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!

CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo

CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/

CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d

CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc